SelectSIEVE® Libra: A Clinical Study on Food Craving Control, Quality of Life, and Body Composition

SelectSIEVE® Libra: A Clinical Study on Food Craving Control, Quality of Life, and Body Composition

THEhyperglycemia , metabolic syndrome These are increasingly common conditions, linked to poor eating habits, a sedentary lifestyle and insulin resistance. In addition to increasing the risk of 2 type diabetes e cardiovascular diseases, have a significant impact on the quality of life, promoting weight gain, tiredness and difficulty controlling appetite.

Drug therapies act on individual parameters (blood sugar, lipids, blood pressure), but often do not address one of the key problems: the food craving, or the compulsion towards sugars and carbohydrates that compromises adherence to diets.

In this context, the 2023 clinical study, designed to evaluate the effectiveness of SelectSIEVE® Libra, innovative phytochemical complex based on White mulberry (Morus alba L.) e Sage (Salvia officinalis L.), two plants traditionally used for metabolic well-being. The clinical trial was conducted on healthy overweight subjects with evidence of food craving.

SelectSIEVE® Libra Scientific Dossier

The available evidence on the efficacy of SelectSIEVE® Libra is divided into three levels:

• In vitro studies: have demonstrated that SelectSIEVE® Libra stimulates the translocation of the GLUT4 transporter into adipocytes, promoting glucose uptake, and induces a physiological insulinotropic effect, improving insulin secretion.
• Acute study (OGTT, 10 healthy volunteers): following oral glucose loading, SelectSIEVE® Libra determined a significant reduction in blood glucose within 60 minutes and a trend towards an increase in insulinemia (AUC +9,6%, p=0,08).
• 56-day clinical study (40 overweight subjects): showed a reduction in food craving, an improvement in quality of life (SF-36) and a decrease in body fat mass.

These preclinical and clinical data confirm a multifactorial mechanism of action, capable of acting both on the regulation of carbohydrate metabolism and on eating behavior.

The clinical study on SelectSIEVE® Libra

The prospective, controlled, single-blind study involved 40 healthy overweight subjectsThe participants took 500 mg/day of SelectSIEVE® Libra (1 capsule in the morning, standardized in hydroxycinnamic acids ≥1% e 1-deoxynojirimycin ≥0,4%) for a period of 56 days. The parameters monitored included:

• Food craving (Food Craving Questionnaire, FCQ-T)
• Life quality (SF-36)
• Body composition (fat mass, lean mass, BMI)
• Blood pressure
• Tolerability and compliance with treatment

Clinical study results

After 56 days of treatment with SelectSIEVE® Libra the following were observed:

• Food craving: significant reduction already after 14 days, with progressive improvement until the end of the study
• Quality of life (SF-36): score increase +4,7% in 28 days e >+10% at 56 days compared to baseline
• Body fat mass: relative reduction −13,9% in 56 days, with a decrease of BMI of −2,9% compared to baseline
• Blood pressure: tendency towards improvement in treated subjects
• Tolerability and compliance: no adverse events reported; adherence ~92%

SelectSIEVE® Libra: Clinical Evidence for Metabolic Management

The 2023 clinical study confirmed that the use of SelectSIEVE® Libra can contribute to the weight management and improvement of the quality of life in overweight subjects, reducing food cravings and favoring the decrease of fat mass.

Thanks to its dual mechanism of action, modulation of glycemic pathways and regulation of appetite, SelectSIEVE® Libra is configured as a phytochemical complex of great interest for the development of innovative, safe and clinically validated supplements.

Full clinical study